Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06070766 · ClinicalTrials.gov registry record

RIVER At Home Ketamine Protocols

A clinical trial of Chronic Pain and Major Depressive Disorder, sponsored by RIVER Foundation.

Recruiting
Registry status
50,000
Enrollment target
2
Study locations

NCT06070766: Recruiting study of Chronic Pain and Major Depressive Disorder, sponsored by RIVER Foundation.

NCT06070766 is a study of Chronic Pain and Major Depressive Disorder that is actively recruiting participants, run by RIVER Foundation. The registered enrollment target is 50,000 participants, above the 606-participant average among 301 other Chronic Pain trials with a reported enrollment target (8151% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06070766, a study of Chronic Pain and Major Depressive Disorder, is actively recruiting participants, sponsored by RIVER Foundation.

RECRUITING
Registry status
50,000 participants
Enrollment target
2
Study locations

Study Summary

Multiple site studies with the recruitment of other sub-investigators and sites. It's sobering to consider how chronic illness makes us more vulnerable to suicidal thoughts and behavior. However, the existence of multiple risk factors also means that there are numerous ways to intervene. Addressing and improving even one risk area will reverberate and improve other areas and the quality of life. RIVER Foundation is completing a 500-participant pilot study researching the safety of oral and nasal ketamine at home with no therapy. The pilot study examined three psychological scales: P.H.Q. 9, G.A.D. 7, and PCL5 scores. The interim report will be available in Nov 2023 with a final report in June 2024. The lack of knowledge for the average medical practitioner makes ketamine a boutique medicine, often costly and unaffordable to those in need. Yet daily medical providers are eliminating ketamine as a choice in the treatment of chronic conditions. The pilot study demonstrated the who, and where. The who, was adults with a chronic condition. The pilot study demonstrated the majority of those who could use ketamine are not receiving it due to cost. According to the 500-participant study, ketamine is safe and effective for at-home use thus demonstrating the where (at home with no supervision).

Primary Outcome

The use of psychological scales to measure participants' mental health with the use of ketamine. The Patient Health Questionnaire-9 (PHQ9), Patient Health Questionnaire 9 has a possible range of 0-27. Zero being no depression and 27 being severe depression. A multiline graph will show the results of PHQ9 will be produced.

Interventions

  • DRUG Ketamine

Study Locations (2)

Montana

  • RIVER Foundation - Bigfork
  • RIVER Telehealth - Helena

Trial Details

FieldValue
Enrollment Target 50,000 participants
Start Date 2023-10-01
Est. Completion 2029-04-01
RIVER Foundation

2 total trials

What NCT06070766 shows while recruiting

NCT06070766 is an observational study that tracks outcomes without assigning an intervention. Its 50,000 participants enrollment target places it among the larger protocols in the corpus, above the 606-participant average among 301 other Chronic Pain trials with a reported enrollment target (8151% higher).

The record links to 6 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.

NCT06070766 reports a single indexed study location in Montana.

Frequently Asked Questions

What is clinical trial NCT06070766 about?

NCT06070766 is a clinical study titled "RIVER At Home Ketamine Protocols". Multiple site studies with the recruitment of other sub-investigators and sites. It's sobering to consider how chronic illness makes us more vulnerable to suicidal thoughts and behavior. However, the existence of multiple risk factors also means that there are numerous ways to intervene. Addressing ...

What is the current status of trial NCT06070766?

This trial is currently recruiting. The enrollment target is 50,000 participants. The study started on 2023-10-01. Estimated completion is 2029-04-01.

What conditions does trial NCT06070766 study?

This clinical trial studies the following conditions: Chronic Pain, Major Depressive Disorder, Post Traumatic Stress Disorder, Anxiety Disorders, Chronic Disease.

What interventions are being tested in trial NCT06070766?

The interventions under investigation include: Ketamine (DRUG).

Who is sponsoring clinical trial NCT06070766?

This trial is sponsored by RIVER Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06070766 being conducted?

This trial has 2 study locations across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06070766's enrollment target sits among peer trials

50,000 2nd of 301 higher than 299 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00500123 · 50,000 participants

    The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

  • NCT01885299 · 50,000 participants

    RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

  • NCT03452774 · 50,000 participants

    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • NCT04629586 · 50,000 participants

    The T1D Exchange Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06070766, the US trial registry maintained by the National Library of Medicine. NCT06070766 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.